Scroll

loxapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
psychoactive	1613	1977-10-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: loxapine loxapin oxilapine loxapine succinate cloxazepine loxitane adasuve loxapine hydrochloride loxapine HCl loxipine maleate	An antipsychotic agent used in SCHIZOPHRENIA. Molecular weight: 327.81 Formula: C18H18ClN3O CLOGP: 3.68 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 28.07 ALOGS: -3.50 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

loxapine
loxapin
oxilapine
loxapine succinate
cloxazepine
loxitane
adasuve
loxapine hydrochloride
loxapine HCl
loxipine maleate

An antipsychotic agent used in SCHIZOPHRENIA.

Molecular weight: 327.81
Formula: C18H18ClN3O
CLOGP: 3.68
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 28.07
ALOGS: -3.50
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
9.10	mg	Inhal.powder
0.10	g	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	378.17	37.79	146	3836	59509	56228576
Poisoning deliberate	377.72	37.79	96	3886	9857	56278228
Neuroleptic malignant syndrome	221.21	37.79	65	3917	11413	56276672
Extrapyramidal disorder	153.51	37.79	50	3932	12306	56275779
Hepatocellular injury	146.76	37.79	59	3923	26455	56261630
Cholestasis	128.88	37.79	54	3928	26859	56261226
Somnolence	117.55	37.79	95	3887	163318	56124767
Oculogyric crisis	111.34	37.79	25	3957	1499	56286586
Toxicity to various agents	104.50	37.79	102	3880	224462	56063623
Intestinal obstruction	94.68	37.79	44	3938	27927	56260158
Tachycardia	74.79	37.79	61	3921	105815	56182270
Pneumonia aspiration	71.15	37.79	38	3944	32373	56255712
Intentional overdose	69.71	37.79	49	3933	68068	56220017
Benzodiazepine drug level increased	69.69	37.79	12	3970	176	56287909
Catatonia	65.67	37.79	20	3962	3944	56284141
Altered state of consciousness	65.04	37.79	32	3950	22989	56265096
Miosis	63.31	37.79	22	3960	6570	56281515
Galactorrhoea	61.76	37.79	19	3963	3876	56284209
Hypothermia	59.56	37.79	25	3957	12445	56275640
Hyperprolactinaemia	58.64	37.79	18	3964	3643	56284442
Brain death	57.86	37.79	17	3965	2966	56285119
Faecaloma	56.99	37.79	21	3961	7420	56280665
Hepatic cytolysis	55.92	37.79	23	3959	10883	56277202
Cardio-respiratory arrest	52.44	37.79	38	3944	55283	56232802
Antipsychotic drug level above therapeutic	49.68	37.79	12	3970	989	56287096
Rhabdomyolysis	48.08	37.79	32	3950	40626	56247459
Hyperthermia	47.73	37.79	19	3963	8266	56279819
Intestinal pseudo-obstruction	47.08	37.79	11	3971	786	56287299
Hypotension	47.03	37.79	72	3910	250436	56037649
Dystonia	46.58	37.79	21	3961	12400	56275685
Urinary retention	45.53	37.79	27	3955	28047	56260038
Overdose	45.19	37.79	46	3936	105784	56182301
Suicide attempt	42.20	37.79	34	3948	57802	56230283
Cardiogenic shock	41.12	37.79	21	3961	16304	56271781
Myocarditis septic	39.67	37.79	6	3976	36	56288049
Amenorrhoea	39.54	37.79	17	3965	8969	56279116
Asphyxia	39.45	37.79	15	3967	5774	56282311

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	316.07	37.89	158	6300	40992	31649894
Therapeutic product effect variable	267.46	37.89	65	6393	1873	31689013
Antipsychotic drug level below therapeutic	264.94	37.89	65	6393	1950	31688936
Disinhibition	251.02	37.89	66	6392	2627	31688259
Akathisia	241.28	37.89	80	6378	7173	31683713
Obsessive-compulsive disorder	232.62	37.89	71	6387	4866	31686020
Euphoric mood	207.50	37.89	65	6393	4855	31686031
Increased appetite	191.26	37.89	65	6393	6279	31684607
Neuroleptic malignant syndrome	169.40	37.89	78	6380	16791	31674095
Poisoning deliberate	148.58	37.89	56	6402	7288	31683598
Wrong patient received product	134.25	37.89	40	6418	2519	31688367
Suicide attempt	130.85	37.89	86	6372	37162	31653724
Hepatocellular injury	128.58	37.89	70	6388	21474	31669412
Rhabdomyolysis	117.92	37.89	100	6358	63481	31627405
Extrapyramidal disorder	116.74	37.89	54	6404	11724	31679162
Miosis	99.87	37.89	44	6414	8526	31682360
Therapeutic product effect incomplete	98.39	37.89	77	6381	43619	31647267
Intestinal obstruction	85.76	37.89	53	6405	20557	31670329
Dyslipidaemia	84.82	37.89	36	6422	6370	31684516
Leukaemia	82.49	37.89	31	6427	3994	31686892
Faecaloma	81.62	37.89	32	6426	4624	31686262
Leukopenia	79.66	37.89	77	6381	57751	31633135
Obesity	77.29	37.89	40	6418	11060	31679826
Toxicity to various agents	76.25	37.89	134	6324	181353	31509533
Hypothermia	74.04	37.89	37	6421	9507	31681379
Prescribed overdose	72.38	37.89	36	6422	9156	31681730
Product use in unapproved indication	68.07	37.89	92	6366	99079	31591807
Somnolence	66.35	37.89	91	6367	99354	31591532
Weight increased	61.59	37.89	80	6378	82867	31608019
Colitis ischaemic	60.73	37.89	28	6430	6024	31684862
Hyperleukocytosis	57.15	37.89	19	6439	1710	31689176
Pneumonia aspiration	56.00	37.89	53	6405	38673	31652213
Subileus	53.99	37.89	21	6437	2969	31687917
Fatigue	50.54	37.89	5	6453	335201	31355685
Electrocardiogram QT prolonged	49.30	37.89	49	6409	37938	31652948
Necrotising colitis	48.68	37.89	15	6443	1057	31689829
Hyperthermia	44.85	37.89	27	6431	9977	31680909
Bradypnoea	42.86	37.89	17	6441	2530	31688356
Tachycardia	42.36	37.89	64	6394	76143	31614743
Blood creatine phosphokinase increased	41.76	37.89	47	6411	41927	31648959
Congestive cardiomyopathy	39.71	37.89	22	6436	6960	31683926
Mydriasis	38.23	37.89	21	6437	6531	31684355

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	690.78	35.79	304	9103	91540	70827497
Poisoning deliberate	490.98	35.79	152	9255	16908	70902129
Neuroleptic malignant syndrome	379.22	35.79	139	9268	25868	70893169
Extrapyramidal disorder	277.03	35.79	104	9303	20646	70898391
Hepatocellular injury	268.24	35.79	128	9279	45963	70873074
Somnolence	190.32	35.79	185	9222	215421	70703616
Rhabdomyolysis	188.15	35.79	131	9276	95629	70823408
Intestinal obstruction	178.78	35.79	92	9315	38733	70880304
Miosis	171.29	35.79	66	9341	14035	70905002
Faecaloma	141.65	35.79	53	9354	10398	70908639
Pneumonia aspiration	135.96	35.79	91	9316	62198	70856839
Hypothermia	134.50	35.79	62	9345	20532	70898505
Wrong patient received product	124.86	35.79	39	9368	4441	70914596
Tachycardia	110.55	35.79	120	9287	158426	70760611
Toxicity to various agents	107.49	35.79	186	9221	381986	70537051
Akathisia	106.03	35.79	45	9362	12248	70906789
Hyperthermia	95.93	35.79	46	9361	16625	70902412
Cholestasis	92.73	35.79	65	9342	47807	70871230
Catatonia	91.43	35.79	36	9371	8097	70910940
Subileus	87.55	35.79	31	9376	5196	70913841
Necrotising colitis	80.57	35.79	20	9387	975	70918062
Cardio-respiratory arrest	80.44	35.79	82	9325	100595	70818442
Altered state of consciousness	79.04	35.79	55	9352	39967	70879070
Fatigue	78.39	35.79	9	9398	824310	70094727
Oculogyric crisis	77.33	35.79	24	9383	2674	70916363
Blood creatine phosphokinase increased	70.25	35.79	61	9346	61202	70857835
Suicide attempt	67.60	35.79	67	9340	79443	70839594
Bladder dilatation	67.58	35.79	20	9387	1897	70917140
Asphyxia	67.08	35.79	31	9376	10311	70908726
Congestive cardiomyopathy	65.45	35.79	31	9376	10895	70908142
Hyperleukocytosis	64.85	35.79	20	9387	2181	70916856
Electrocardiogram QT prolonged	61.25	35.79	65	9342	83452	70835585
Benzodiazepine drug level increased	60.00	35.79	12	9395	213	70918824
Hepatic cytolysis	59.34	35.79	35	9372	19157	70899880
Agitation	58.66	35.79	67	9340	93308	70825729
Bradypnoea	57.30	35.79	23	9384	5436	70913601
Antipsychotic drug level below therapeutic	56.29	35.79	15	9392	970	70918067
Pain	54.66	35.79	9	9398	628807	70290230
Galactorrhoea	52.67	35.79	19	9388	3359	70915678
Respiratory acidosis	52.04	35.79	26	9381	10255	70908782
Distal intestinal obstruction syndrome	51.76	35.79	13	9394	665	70918372
Intentional overdose	50.94	35.79	64	9343	98371	70820666
Faecal vomiting	50.82	35.79	14	9393	1027	70918010
Colitis ischaemic	49.61	35.79	28	9379	14109	70904928
Therapeutic product effect variable	48.12	35.79	15	9392	1695	70917342
Urinary retention	47.88	35.79	46	9361	52474	70866563
Disinhibition	47.67	35.79	16	9391	2285	70916752
Confusional state	46.82	35.79	111	9296	284287	70634750
Housebound	45.93	35.79	11	9396	461	70918576
Aggression	45.24	35.79	43	9364	48403	70870634
Brain death	44.79	35.79	19	9388	5159	70913878
Dystonia	43.44	35.79	29	9378	19677	70899360
Drug interaction	42.67	35.79	129	9278	381312	70537725
Intestinal ischaemia	42.62	35.79	24	9383	12040	70906997
Hyperprolactinaemia	40.87	35.79	17	9390	4396	70914641
Dyspnoea	40.87	35.79	26	9381	770034	70149003
Product use in unapproved indication	40.85	35.79	87	9320	207391	70711646
Psychotic disorder	40.12	35.79	36	9371	37665	70881372
Arthralgia	39.91	35.79	9	9398	503381	70415656
Antipsychotic drug level above therapeutic	38.01	35.79	13	9394	1966	70917071
Drug abuse	37.75	35.79	69	9338	147187	70771850
Diabetic hyperosmolar coma	36.09	35.79	10	9397	749	70918288
Myocarditis septic	35.90	35.79	6	9401	36	70919001

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AH01	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diazepines, oxazepines, thiazepines and oxepines
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:35476	neuroleptics
CHEBI has role	CHEBI:48561	dopaminergic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bipolar disorder	indication	13746004	DOID:3312
Schizophrenia	indication	58214004	DOID:5419
Alcoholism	contraindication	7200002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Glaucoma	contraindication	23986001	DOID:1686
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Tardive dyskinesia	contraindication	102449007
Seizure disorder	contraindication	128613002
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Coma	contraindication	371632003
Carcinoma of female breast	contraindication	447782002
Pigmentary Retinopathy	contraindication
Drug Induced CNS Depression	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.59	Basic
pKa2	3.24	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	8.62	CHEMBL	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	7.68	CHEMBL	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.24	PDSP
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.61	PDSP
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	8	IUPHAR
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.82	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.51	PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.97	PDSP
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	IC50	7.66	CHEMBL
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	7.13	PDSP
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	8.20	IUPHAR
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	6.68	PDSP
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	5.30	PDSP
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		IC50	5.26	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.38	PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.91	PDSP
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.09	PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.83	PDSP
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	6.41	PDSP
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.46	PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.10	PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	ANTAGONIST	Ki	8.31	CHEMBL
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	6.72	PDSP
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	7.28	PDSP
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.11	PDSP
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		Ki	5.85	PDSP
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN		IC50	4.70	CHEMBL
Potassium channel subfamily T member 1	Ion channel	Q5JUK3	KCNT1_HUMAN	ACTIVATOR	EC50	5.36	IUPHAR
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.27	PDSP
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.82	PDSP
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	7.68	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		IC50	8.22	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	7.37	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		IC50	6	CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	6	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	7.80	IUPHAR
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		IC50	7.74	CHEMBL

External reference:

ID	Source
4019805	VUID
N0000147894	NUI
D00794	KEGG_DRUG
27833-64-3	SECONDARY_CAS_RN
4017917	VANDF
4017918	VANDF
4019805	VANDF
C0024056	UMLSCUI
CHEBI:50841	CHEBI
CHEMBL831	ChEMBL_ID
CHEMBL1201155	ChEMBL_ID
DB00408	DRUGBANK_ID
D008152	MESH_DESCRIPTOR_UI
3964	PUBCHEM_CID
205	IUPHAR_LIGAND_ID
2610	INN_ID
54810-23-0	SECONDARY_CAS_RN
LER583670J	UNII
1364415	RXNORM
1308	MMSL
1346	MMSL
196711	MMSL
29026	MMSL
4999	MMSL
5000	MMSL
d00897	MMSL
001522	NDDF
001523	NDDF
001524	NDDF
1971003	SNOMEDCT_US
30745005	SNOMEDCT_US
372789006	SNOMEDCT_US
59270007	SNOMEDCT_US
CHEMBL1201060	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1394	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1395	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1396	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1397	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0369	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0370	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0371	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0372	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-585	TABLET	5 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-586	TABLET	10 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-587	TABLET	25 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-588	TABLET	50 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	17856-1397	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-436	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-437	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-438	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-439	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4701	CAPSULE	10 mg	ORAL	ANDA	21 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4701	CAPSULE	10 mg	ORAL	ANDA	21 sections
Adasuve	HUMAN PRESCRIPTION DRUG LABEL	1	51097-001	AEROSOL, POWDER	10 mg	RESPIRATORY (INHALATION)	NDA	31 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-890	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-891	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-892	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-893	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	68151-2875	CAPSULE	5 mg	ORAL	ANDA	18 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0283	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0283	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0346	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0346	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0347	CAPSULE	25 mg	ORAL	ANDA	20 sections